ESTRIGENIX THERAPEUTICS, INC.

Wauwatosa, WI · Biotech · Private

EGX358, a novel selective estrogen receptor beta (ERβ) agonist small molecule therapeutic

Claim this profile

Follows are private to you and power your alerts

Updated · estrigenix.com

Sector
Biotech
Headquarters
Wauwatosa, WI
Total capital
$598K
Federal grants
$598K
2 awards · 2022
Rank in peer group#178 of 502
Private capital raised
None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
Federal contracts
None on recordNo federal contract awards found.
Granted patents
None on recordNo USPTO grants. Applications publish after 18 months.

Capital timeline

2022FEDERAL ↑EQUITY ↓Cumulative $598K$299K$299K
2022FEDERAL ↑EQUITY ↓Cumulative $598K$299K$299K

Latest events

  • Federal grantHealth and Human S · Phase I · Development of EGX358, an ER-beta Agonist to Treat Hot Flashes and Menopause-Related Memory Loss$299K
  • Federal grantHealth and Human S · Phase I · Development of EGX358, an ER-beta Agonist to Treat Hot Flashes & Menopause-Related Memory Loss$299K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 502 peers

Line = median

Biotech · Molecule

  • Federal grants#178 · top 35%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

No founders are linked to this company yet.

Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.

Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026

Claim this profile to add your team

What it has protected

No granted patents are on record.

USPTO usually publishes applications 18 months after filing, so recent applications may not be visible yet. Patents assigned under a different entity name won’t match.

Checked: USPTO granted patents and published applications · Oct 23, 2026

  • NANOMEDTRIX LLCSimilar federal contract value in Biotech · null in contracts
  • Boundless Bio, Inc.Similar federal contract value in Biotech · null in contracts
  • Treeline BiosciencesSimilar federal contract value in Biotech · null in contracts
  • Cognito Therapeutics Ltd.Similar federal contract value in Biotech · null in contracts
  • Kyverna TherapeuticsSimilar federal contract value in Biotech · null in contracts
  • Gilgamesh PharmaSimilar federal contract value in Biotech · null in contracts

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .